Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care

Hellings, Peter W. ; Alobid, Isam ; Anselmo-Lima, Wilma T. ; Bernal-Sprekelsen, Manuel ; Bjermer, Leif LU ; Caulley, Lisa ; Chaker, Adam ; Constantinidis, Jannis ; Conti, Diego M. and De Corso, Eugenio , et al. (2023) In Allergy: European Journal of Allergy and Clinical Immunology
Abstract

Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes,... (More)

Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
aspirin intolerance, biologics, corticosteroids, CRSwNP, sinus surgery
in
Allergy: European Journal of Allergy and Clinical Immunology
publisher
Wiley-Blackwell
external identifiers
  • pmid:38108602
  • scopus:85179909440
ISSN
0105-4538
DOI
10.1111/all.15982
language
English
LU publication?
yes
id
5918b002-4334-47eb-994b-2191e104b25b
date added to LUP
2024-01-10 11:18:19
date last changed
2024-04-25 07:16:33
@article{5918b002-4334-47eb-994b-2191e104b25b,
  abstract     = {{<p>Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.</p>}},
  author       = {{Hellings, Peter W. and Alobid, Isam and Anselmo-Lima, Wilma T. and Bernal-Sprekelsen, Manuel and Bjermer, Leif and Caulley, Lisa and Chaker, Adam and Constantinidis, Jannis and Conti, Diego M. and De Corso, Eugenio and Desrosiers, Martin and Diamant, Zuzana and Gevaert, Philippe and Han, Joseph K. and Heffler, Enrico and Hopkins, Claire and Landis, Basile N. and Lourenco, Olga and Lund, Valerie and Luong, Amber U. and Mullol, Joaquim and Peters, Anju and Philpott, Carl and Reitsma, Sietze and Ryan, Dermot and Scadding, Glenis and Senior, Brent and Tomazic, Peter Valentin and Toskala, Elina and Van Zele, Thibaut and Viskens, An Sofie and Wagenmann, Martin and Fokkens, W. J.}},
  issn         = {{0105-4538}},
  keywords     = {{aspirin intolerance; biologics; corticosteroids; CRSwNP; sinus surgery}},
  language     = {{eng}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Allergy: European Journal of Allergy and Clinical Immunology}},
  title        = {{EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care}},
  url          = {{http://dx.doi.org/10.1111/all.15982}},
  doi          = {{10.1111/all.15982}},
  year         = {{2023}},
}